Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors
Citations Over TimeTop 10% of 2025 papers
Abstract
Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine administration. This document aims to provide dermatologists and other healthcare practitioners with comprehensive practical vaccination recommendations for adults and adolescent patients with atopic dermatitis who are receiving or are about to receive treatment with JAK inhibitors. While inactivated vaccines are safe and recommended during JAK treatment, live attenuated vaccines are contraindicated unless treatment is temporarily discontinued according to clinical guidelines. It is crucial to follow vaccination guidelines established by official agencies and tailor them to individual patient needs. Careful consideration and follow-up are essential to ensure patient safety and optimal therapeutic outcomes.
Related Papers
- → Atopic dermatitis phenotypes and the need for personalized medicine(2017)154 cited
- → Allergic march in children: Atopic dermatitis in Japanese children with bronchial asthma(1996)5 cited
- Expression and significance of interleukin 4 in patients with atopic dermatitis(2009)
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)
- → Research Trends on Atopic Dermatitis an Autoimmune Disease and Exercise(2024)